GERMANTOWN, Md., Jan. 22 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief Scientific Officer of Neuralstem, will discuss NSI-566, the Company’s stem cell therapy program, at the Cell and Gene Therapy World at the Hyatt Regency in Miami, FL. The presentation [...]
GERMANTOWN, Md., Jan. 5 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, chief science officer Neuralstem, will present at the Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology at the Marines’ Memorial Club in San Francisco, CA. The presentation is scheduled [...]
GERMANTOWN, Md., Dec. 20 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Xi Chen, Ph.D., has been appointed to its Board of Directors, effective immediately. Dr. Chen was appointed by Tianjin to replace Zhang Zhuo as the director appointee of the Series A Convertible [...]
GERMANTOWN, Md., Dec. 5 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that additional safety, efficacy and tolerability data from its exploratory Phase 2 clinical trial examining the efficacy of NSI-189 at 40 mg once daily (QD) and 40 mg twice daily (BID) compared to [...]
GERMANTOWN, Md., Nov. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held [...]
GERMANTOWN, Md., Nov. 13 (Korea Bizwire) — Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the three and nine month periods ended September 30, 2017. “We continue to evaluate the full Phase 2 data set for NSI-189 [...]
GERMANTOWN, Md., Nov. 8 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the appointment of David Recker, MD, FACR, FACP, as Chief Medical Officer. “Given his extensive experience in the biopharma industry, Dr. Recker brings to Neuralstem an expertise that will be critical to the [...]
GERMANTOWN, Md., Sept. 25 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Zhang Zhuo and Cristina Csimma, PharmD, MHP, have been appointed to its Board of Directors, effective September 18, 2017. “I’m very pleased to welcome Mr. Zhang and Dr. Csimma to our Board,” [...]
GERMANTOWN, Md., Feb. 28 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announced the recent publication of preclinical data on NSI-189 in Journal of Cellular Physiology. The study demonstrated that NSI-189 improved behavioral function recovery and enhanced hippocampal synaptic [...]
GERMANTOWN, Md., Feb. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new [...]